Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

147 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Alternative prostate cancer grading systems incorporating percent pattern 4/5 (IQ-Gleason) and cribriform architecture (cGrade) improve prediction of outcome after radical prostatectomy.
Seyrek N, Hollemans E, Andrinopoulou ER, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Remmers S, Schoots IG, van Leenders GJLH. Seyrek N, et al. Among authors: osanto s. Virchows Arch. 2022 Jun;480(6):1149-1157. doi: 10.1007/s00428-022-03301-y. Epub 2022 Feb 14. Virchows Arch. 2022. PMID: 35157140 Free PMC article.
Real-life data on the impact of successful downstaging in patients with hepatocellular carcinoma: A Dutch Multicenter Study.
Broekhoven AGC, Fiocco M, Sprengers D, Takkenberg RB, van Meer S, van Erpecum KJ, Ramsoekh D, Verspaget HW, Burgmans MC, Osanto S, Baranski AG, van Hoek B, Coenraad MJ. Broekhoven AGC, et al. Among authors: osanto s. Eur J Intern Med. 2022 Mar;97:56-61. doi: 10.1016/j.ejim.2021.12.009. Epub 2021 Dec 21. Eur J Intern Med. 2022. PMID: 34952770 Free article.
Cribriform architecture outperforms Gleason pattern 4 percentage and tertiary Gleason pattern 5 in predicting the outcome of Grade Group 2 prostate cancer patients.
Seyrek N, Hollemans E, Osanto S, Pelger RCM, van der Poel HG, Bekers E, Bangma CH, Rietbergen J, Roobol MJ, Schoots IG, van Leenders GJLH. Seyrek N, et al. Among authors: osanto s. Histopathology. 2022 Feb;80(3):558-565. doi: 10.1111/his.14590. Epub 2021 Dec 14. Histopathology. 2022. PMID: 34706119 Free PMC article.
An exploratory first-in-man study to investigate the pharmacokinetics and safety of liposomal dexamethasone at a 2- and 1-week interval in patients with metastatic castration resistant prostate cancer.
Vrouwe JPM, Kamerling IMC, van Esdonk MJ, Metselaar JM, Stuurman FE, van der Pluijm G, Burggraaf J, Osanto S. Vrouwe JPM, et al. Among authors: osanto s. Pharmacol Res Perspect. 2021 Oct;9(5):e00845. doi: 10.1002/prp2.845. Pharmacol Res Perspect. 2021. PMID: 34414692 Free PMC article.
147 results